The PI3-kinase inhibitor in combination with the estrogen receptor (ER) antagonist is FDA-approved for the treatment of patients with PIK3CA mutant ER+/HER2− breast cancer and the presence of PIK3CA/TP53 mutations has evidence of prognostic relevance (42, 43). This evidence concerns the gene TP53 and breast cancer.